MedCity News February 15, 2022
Expect more clinical trial sponsors to embrace these technologies as the industry sees wider adoption of decentralized clinical trials.
Before the pandemic, many sponsors were hesitant to embrace decentralized clinical trial (DCT) elements in their research. They were concerned that technology-driven research might not meet regulatory standards, and that data captured on personal devices would not be secure.
Covid-19 changed all of that. The closure of sites forced sponsors to embrace telehealth, wearables and remote monitoring. It was a difficult transition, but it helped life sciences companies see the value that DCT technology brings to trial designs.
That experience accelerated the industry’s technology adoption by years, and we expect the transformation to continue in the year(s) ahead. One report found...
Today's Sponsors
Today's Sponsor